ReviewMedical oncology (Northwood, London, England)2017
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Review in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03587129 (Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer), which is not on this map. Cited by 106 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
Who cites it
106 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Liposomal delivery of gene therapy for ovarian cancer: a systematic review.Reproductive biology and endocrinology : RB&E · 2023Pooled it
- Anticancer Potentials of the Lignan Magnolin: A Systematic Review.Molecules (Basel, Switzerland) · 2023Pooled it
- Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis.Journal of ovarian research · 2021Pooled it
- The Accuracy of Single MicroRNAs in Peripheral Blood to Diagnose Ovarian Cancer: An Updated Meta-Analysis.Disease markers · 2020Pooled it
- Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer.Medical oncology (Northwood, London, England) · 2022Trial
- Article
- LncRNA CDIPTOSP-induced destabilization of KLF17 promotes ovarian cancer progression through STAU1-mediated mRNA decay.American journal of translational research · 2026Article
- Molecular Subtype Classification and Mechanistic Investigation Based on Ferroptosis-Related lncRNAs in Ovarian Cancer.Genetics research · 2026Article
- Reprogramming Transcriptional Networks via CREB1 Lactylation at K122 Activates HMGB1-Mediated NETosis and Chemoresistance.International journal of biological sciences · 2026Article
- Evaluation of drug options for epithelial ovarian cancer (EOC) treatment using the analytical hierarchy process improves decision-making transparency.Discover oncology · 2025Article
- Review
- RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer.Scientific reports · 2025Article
- Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study.Oncology and therapy · 2025Article
- Overcoming platinum-resistant ovarian cancer targeting the activated JAK-STAT pathways via extracellular vesicles.Communications biology · 2025Article
- CT-based radiomics model to predict platinum sensitivity in epithelial ovarian carcinoma: a multicentre study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Review
- A real-world retrospective cohort study: the clinical outcomes and characteristics of platinum-resistant recurrent ovarian cancer.Translational cancer research · 2025Article
- NCAPH promotes glucose metabolism reprogramming and cell stemness in ovarian cancer cells through the MEK/ERK/PD-L1 pathway.Journal of ovarian research · 2025Article
- Network pharmacology-based strategy to reveal the mechanism of pinocembrin against ovarian cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Ovarian cancer targeted therapy: current landscape and future challenges.Frontiers in oncology · 2025Review
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ovarian cancer, which ranks fifth in cancer deaths among women, is the most lethal gynecologic malignancy. Epithelial ovarian cancer (EOC) is the most common histologic type, with the 5-year survival for all stages estimated at 45.6%. This rate increases to more than 70% in the minority of patients who are diagnosed at an early stage, but declines to 35% in the vast majority of patients diagnosed at advanced stage. Recurrent EOC is incurable. Platinum sensitivity (or lack thereof) is a major determinant of prognosis. The current standard treatment is primary surgery followed by platinum-based chemotherapy. In recurrent platinum-resistant/platinum-refractory EOC, sequential single-agent salvage chemotherapy is superior to multiagent chemotherapy. Multiagent regimens increase toxicity without clear benefit; however, no preferred sequence of single agents is recommended. The impact of targeted therapies and immunotherapies on progression-free survival and overall survival, which remains dismal, is under active investigation. Currently, clinical trials offer the best hope for the development of a new treatment paradigm in this recalcitrant disease.
Indexed as
Identifiers
28444622What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.